试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-06-13
A Study to Evaluate LB1148 for Return of Bowel Function in Subjects Undergoing Bowel Resection
编号:NCT05470387登记状态:提前终止企业 / 申办者:Palisade Bio
药物 / 成分:LB1148、Placebo
登记的停止原因(原文):Company decision
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-06-12
To Evaluate the Optimal Timing of Postoperative Radiotherapy in Patients With IIIA(N2) Non-Small Cell Lung Cancer
编号:NCT02974426登记状态:提前终止企业 / 申办者:Shanghai Chest Hospital
药物 / 成分:PORT-first、PORT-last、Platinum-based two drug chemotherapy (cisplatin/carboplatin + vinorelbine or cisplatin/carboplatin + pemetrexed regimen)
登记的停止原因(原文):Enrollment was delayed and the number of eligible patients significantly declined with the use of neoadjuvant or adjuvant ICIs and TKIs therapies. Thus, this trial was closed due to insufficient accrual.
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-06-12
In Vivo PARP-1 Expression With 18F-FTT PET/CT in Pancreatic Cancer
编号:NCT03492164登记状态:提前终止企业 / 申办者:Abramson Cancer Center at Penn Medicine
药物 / 成分:[18F]FluorThanatrace ([18F]FTT)
登记的停止原因(原文):Early analysis of images after 6 patients showed no activity of the radiotracer in this patient population.
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-06-12
Fecal Microbial Transplantation for the Treatment of Fecal Incontinence in Women
编号:NCT04201821登记状态:提前终止企业 / 申办者:University of Pennsylvania
药物 / 成分:fecal microbial transplantation (FMT)
登记的停止原因(原文):Administrative reasons
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-06-12
A Study of Sacituzumab With Chemoimmunotherapy to Treat Advanced Triple-Negative Breast Cancer After Prior Therapies
编号:NCT04927884登记状态:提前终止企业 / 申办者:ImmunityBio, Inc.
药物 / 成分:N-803、PD-L1 t-haNK、Sacituzumab Govitecan-Hziy、Cyclophosphamide
登记的停止原因(原文):low enrollment
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-06-12
HB-302/HB-301 Therapy in Participants With Metastatic Castration-Resistant Prostate Cancer
编号:NCT05553639登记状态:提前终止企业 / 申办者:Hookipa Biotech GmbH
药物 / 成分:HB-302/HB-301 Alternating 2-Vector Therapy
登记的停止原因(原文):Decision by the company to terminate the H-300-001 study early for non-safety related reasons.
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-06-12
An Open-label Study to Assess the Long-term Safety, Tolerability, Effectiveness, and Durability of Effect of KarXT in Patients With DSM-5 Diagnosis of Schizophrenia
编号:NCT05643170登记状态:提前终止企业 / 申办者:Karuna Therapeutics, Inc., a Bristol Myers Squibb company
药物 / 成分:Xanomeline and Trospium Chloride Capsules
登记的停止原因(原文):Company's business decision.
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-06-11
A Study of MK-0822 in Postmenopausal Women With Osteoporosis to Assess Fracture Risk (MK-0822-018)
编号:NCT00529373登记状态:提前终止企业 / 申办者:Merck Sharp & Dohme LLC
药物 / 成分:Odanacatib、Placebo for Odanacatib、Vitamin D3、Calcium carbonate
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-06-11
Supplements for Controlling Resistance to Insulin
编号:NCT00699413登记状态:提前终止企业 / 申办者:University of Southern California
药物 / 成分:nutrition education plus active supplement、nutrition education plus inactive supplement
登记的停止原因(原文):Sponsor decided to withdraw from study.
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-06-11
Topiramate in Neonates Receiving Whole Body Cooling for Hypoxic Ischemic Encephalopathy
编号:NCT01765218登记状态:提前终止企业 / 申办者:Kristin R Hoffman
药物 / 成分:Topiramate、Placebo
登记的停止原因(原文):The study was stopped early due to changes in the UC Davis guidelines on who qualified for therapeutic hypothermia and significant difficulty in recruitment of patients following the COVID19 pandemic.
查看官方原始记录 ↗